2024年6月17日 · Arexvy is an RSV vaccine used to prevent severe Respiratory Syncytial Virus Vaccine (RSV) symptoms in older adults to reduce the risk of hospitalization or death from RSV. Arexvy vaccine is made by GSK.

2023年11月27日 · Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a prescription vaccine to help prevent RSV. Learn about cost, dosage, and more.

2024年6月17日 · Arexvy was the first vaccine approved to prevent respiratory syncytial virus (RSV). RSV is a common virus that usually causes mild cold-like symptoms. These symptoms can be more...

2024年8月22日 · AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 60 years of age...

2024年6月11日 · Arexvy and Abrysvo are both RSV vaccines that are approved for use in adults over the age of 60 to reduce their risk of developing lower respiratory tract disease (LRTD). They are also approved for adults aged 50 through 59 years (Arexvy) or aged 18 through 59 (Abrysvo) with certain chronic medical conditions (such as chronic pulmonary disease ...

2025年1月23日 · AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV. (1) For intramuscular use. AREXVY is administered as a single 0.5 mL dose (2.1)

Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of...

What is AREXVY used for? AREXVY is a vaccine that helps to protect adults 60 years of age and older from lower lung disease caused by respiratory syncytial virus (RSV). RSV is a common highly contagious respiratory virus, causing infections of the lungs and breathing passages.

2024年1月11日 · Arexvy is a vaccine given to adults ages 60 years and older to help prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV). Examples of these infections include...

2023年5月3日 · AREXVY is the first approved RSV vaccine for older adults, expanding GSK’s industry-leading vaccine portfolio, which protects millions of people from infectious diseases each year. Our focus now is to ensure eligible older adults in the US can access the vaccine as quickly as possible and to progress regulatory review in other countries.”